Tevogen Bio (NASDAQ:TVGN) Posts Earnings Results, Beats Expectations By $0.39 EPS

Tevogen Bio (NASDAQ:TVGN) posted its earnings results on Friday. The company reported ($1.61) EPS for the quarter, topping analysts’ consensus estimates of ($2.00) by $0.39, FiscalAI reports.

Tevogen Bio Stock Down 15.6%

TVGN stock traded down $1.47 during trading on Friday, hitting $7.95. The company had a trading volume of 20,555 shares, compared to its average volume of 27,610. The firm has a market cap of $33.07 million, a PE ratio of -0.84 and a beta of 0.09. Tevogen Bio has a 1-year low of $4.14 and a 1-year high of $75.50. The firm has a 50-day moving average price of $6.33 and a 200-day moving average price of $14.49.

Analysts Set New Price Targets

TVGN has been the topic of a number of research analyst reports. Wall Street Zen cut Tevogen Bio to a “strong sell” rating in a research report on Saturday, March 21st. D. Boral Capital cut Tevogen Bio from a “buy” rating to a “hold” rating in a research report on Wednesday, March 4th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Tevogen Bio in a research report on Monday, April 20th. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Reduce” and a consensus price target of $100.00.

Hedge Funds Weigh In On Tevogen Bio

Several institutional investors have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. increased its position in Tevogen Bio by 126.0% in the 4th quarter. Goldman Sachs Group Inc. now owns 273,694 shares of the company’s stock valued at $91,000 after acquiring an additional 152,572 shares during the period. Deutsche Bank AG boosted its holdings in Tevogen Bio by 304.1% in the 4th quarter. Deutsche Bank AG now owns 173,734 shares of the company’s stock valued at $57,000 after purchasing an additional 130,738 shares in the last quarter. Finally, Bridgeway Capital Management LLC boosted its holdings in Tevogen Bio by 66.7% in the 3rd quarter. Bridgeway Capital Management LLC now owns 82,500 shares of the company’s stock valued at $65,000 after purchasing an additional 33,000 shares in the last quarter.

Tevogen Bio Company Profile

Tevogen Bio plc (NASDAQ:TVGN) is a clinical-stage biotechnology company focused on developing personalized natural killer (NK) cell immunotherapies for oncology and severe viral diseases. Leveraging proprietary induced pluripotent stem cell (iPSC) and donor-derived NK cell platforms, Tevogen Bio aims to create off-the-shelf cell therapy products that offer scalable and cost-efficient treatment options. The company’s lead candidate, TVGN-484, is an allogeneic NK cell therapy in clinical trials for relapsed or refractory acute myeloid leukemia (AML).

In addition to its lead program in AML, Tevogen Bio’s pipeline includes preclinical NK cell candidates directed against hematological malignancies, solid tumors and viral infections.